Alpha Teknova (TKNO) Reports Prelim Q4 Revenue of $10-$10.1M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Teknova Announces Preliminary Revenue of $10.0 to $10.1 Million for the Fourth Quarter 2021
February 28, 2022 8:15 AM ESTCompany to participate in two upcoming investor conferences in March 2022
HOLLISTER, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced preliminary unaudited revenue for the fourth quarter ended December 31, 2021, of $10.0 to $10.1 million, including Sample Transport of approximately $0.5 million.  Excluding Sample Transport, total unaudited revenue for the fourth quarter ended December 31, 2021, was $9.5 to $9.6 million.
"Our team delivered an outstanding finish to 2021, resulting in... More
